Amanda M Gillum
Overview
Explore the profile of Amanda M Gillum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prasad A, Khudaynazar N, Tantravahi R, Gillum A, Hoffman B
Oncotarget
. 2016 Oct;
7(48):79388-79400.
PMID: 27764820
Squamous cell carcinoma of the head and neck (HNSCC) is characterized by high morbidity and mortality. Treatment failure, drug resistance and chemoradiation toxicity have necessitated the development of alternative treatment...
2.
Prasad A, Shrivastava A, Papadopoulos E, Kuzontkoski P, Reddy M, Gillum A, et al.
Clin Cancer Res
. 2012 Nov;
19(1):85-95.
PMID: 23124440
Purpose: Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma, and new therapeutic strategies are urgently needed. Experimental Design: The effects of ON 013105, a novel benzylstyryl sulfone kinase inhibitor,...
3.
Chun A, Freshwater R, Taft D, Gillum A, Maniar M
Biopharm Drug Dispos
. 2011 Feb;
32(2):99-111.
PMID: 21341279
ON 01210.Na (Ex-RAD®) is a novel small molecule under development by Onconova Therapeutics, Inc. as a radiation protection agent. The purpose of this investigation was to evaluate the effect of...
4.
Barvaux V, Lorigan P, Ranson M, Gillum A, McElhinney R, McMurry T, et al.
Mol Cancer Ther
. 2004 Oct;
3(10):1215-20.
PMID: 15486188
Temozolomide is an alkylating agent that mediates its cytotoxic effects via O(6)-methylguanine (O(6)-meG) adducts in DNA. O(6)-alkylguanine-DNA-alkyltransferase (MGMT) can repair such adducts and therefore constitutes a major resistance mechanism to...
5.
Klasa R, Gillum A, Klem R, Frankel S
Antisense Nucleic Acid Drug Dev
. 2002 Aug;
12(3):193-213.
PMID: 12162702
The components of the apoptotic program are targets for anticancer therapy. Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies (mAb). Oblimersen...